Therapeutic effect of DC-CIK cells combined with S-1 in the treatment of non-small-cell lung cancer

Objective To observe the clinical effect of DC-CIK cells combined with S-1 in the treatment of non-small-cell lung cancer. Methods 76 patients with non-small-cell lung cancer were randomly divided into the observation group and the control group on average. The control group was treated with S-1, and the observation group was treated with DC-CIK cells combined with S-1. For the observation group, the peripheral venous blood was collected before the treatment for DC cells and CIK cells cultivation. The expression of CD4+/CD8+, CD4+ and NK cells in the peripheral blood of the two groups was detected by flow cytometry before the treatment and after one week of the treatments. Besides, the number of white blood cells and platelet count were also measured and the symptoms of non-small-cell lung cancer were observed. Results The percentage of CD4+/CD8+, CD4+ and NK cells in the peripheral blood of the observation group after the treatment was (1.65±1.03), (34.56±8.90) and (18.68±7.98), respectively, which was significantly higher than (1.32±0.70), (29.07±7.15) and (15.28±8.23) in the control group (all P 0.05). The vomiting, leukopenia and thrombocytopenia in the observation group were less than those in the control group (all P<0.05). The one-year survival rate was 52.63% in the observation group which was significant higher than 42.11% in the control group (P<0.05). Conclusions DC-CIK cells combined with S-1 is a safe and effective treatment for non-small-cell lung cancer, which can effectively improve the clinical efficacy and prolong the survival time of patients. Key words: Non-small-cell-lung cancer; S-1; DC-CIK cells; Chemotherapy